Tirzepatide Patent Expiration

Tirzepatide is Used for long-term weight management in adults who are overweight or obese with at least one weight-related comorbid condition. It was first introduced by Eli Lilly And Co in its drug Mounjaro (Autoinjector) on May 13, 2022. Other drugs containing Tirzepatide are Zepbound (Autoinjector), Zepbound, Mounjaro.


Tirzepatide Patents

Given below is the list of patents protecting Tirzepatide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mounjaro US11357820 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Mounjaro US9474780 GIP and GLP-1 co-agonist compounds Jan 05, 2036 Eli Lilly And Co
Mounjaro (autoinjector) US11357820 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Mounjaro (autoinjector) US8734394 Automatic injection device with delay mechanism including dual functioning biasing member Feb 24, 2031 Eli Lilly And Co
Mounjaro (autoinjector) US9402957 Automatic injection device with delay mechanism including dual functioning biasing member Jun 29, 2031 Eli Lilly And Co
Mounjaro (autoinjector) US9474780 GIP and GLP-1 co-agonist compounds Jan 05, 2036 Eli Lilly And Co
Zepbound US11357820 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Zepbound US11918623 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Zepbound US9474780 GIP and GLP-1 co-agonist compounds Jan 05, 2036 Eli Lilly And Co
Zepbound (autoinjector) US11357820 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Zepbound (autoinjector) US11918623 GIP/GLP1 agonist compositions Jun 14, 2039 Eli Lilly And Co
Zepbound (autoinjector) US8734394 Automatic injection device with delay mechanism including dual functioning biasing member Feb 24, 2031 Eli Lilly And Co
Zepbound (autoinjector) US9402957 Automatic injection device with delay mechanism including dual functioning biasing member Jun 29, 2031 Eli Lilly And Co
Zepbound (autoinjector) US9474780 GIP and GLP-1 co-agonist compounds Jan 05, 2036 Eli Lilly And Co


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳